Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of MAX-40070 in Healthy Subjects
NCT05196711Phase 1Unknown
- Sponsor
- Guangzhou Zaiji Medical Technology
- Start
- Feb 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in alopecia areata comparing MAX-40070 with Placebo (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events at 36 Days. Status: unknown.
02
Drugs
MAX-3
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT05196711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05196711.